Friday, September 18, 2015 | 8:30 AM - 4:30 PM
Speakers: George S. Bloom (University of Virginia), Peter Davies (Feinstein Institute for Medical Research), Marc I. Diamond (University of Texas, Southwestern Medical Center), Michael Hutton (Eli Lilly and Company), Khalid Iqbal (New York State Institute for Basic Research in Developmental Disabilities), Hartmuth C. Kolb (Johnson & Johnson, Janssen R&D), Nicole Leclerc (Université de Montréal), Richard Ransohoff (Biogen)
Speakers at this symposium will address novel tau-centered mechanisms of neurodegeneration and new therapeutic approaches for many devastating neurological disorders.
Tuesday, September 29, 2015 | 12:00 PM - 5:00 PM
Speakers: Samie R. Jaffrey (Weill Cornell Medical College), Amy E. Palmer (University of Colorado)
This symposium features state of the art chemical tools and imaging strategies for metal ions, redox signaling species, and metabolites in the cell, cellular delivery and targeting approaches, and their application to studying life processes.
Tuesday, October 27, 2015 | 8:00 AM - 5:00 PM
Speakers: Andras Bauer (Boehringer Ingelheim), Alex Huang (Genentech), Michael Jackson (Sanford-Burnham Medical Research Institute), Bryan Laffitte (Genomics Institute of the Novartis Research Foundation), Jonathan Lee (Eli Lilly), Lorenz Mayr (AstraZeneca), Friedrich Metzger (Hoffmann-La Roche), Aravind Subramanian (Broad Institute), Giulio Superti-Furga (Austrian Academy of Sciences), John Tallarico (Novartis Institutes for Biomedical Research), Robert Temple (US Food and Drug Administration)
This symposium aims to deepen our understanding of phenotypic drug discovery and to foster the exchange of ideas between industry-based and academic research scientists.
Tuesday, July 28, 2015 | 8:30 AM - 6:00 PM
Speakers: Marc D Chioda (Pfizer Inc), Leonard James (Pfizer Inc), Iya Khalil (GNS Healthcare), Michael Matheny (Vanderbilt University), Jason H. Moore (University of Pennsylvania), Nicholas Tatonetti (Columbia University Medical Center), Craig P. Webb (NuMedii, Inc), Chunhua Weng (Columbia University), Diane Wuest (GNS Healthcare)
In the era of precision medicine, analyses of large volumes of data are key to developing targeted and effective therapeutics. This symposium explores how big data and predictive knowledge are used to guide drug development and clinical trials.
Thursday, June 11, 2015 | 8:45 AM - 5:15 PM
Keynote Speaker: Jane A. Driver (Brigham and Women's Hospital)
Speakers: Kurt Brunden (University of Pennsylvania), Stuart Calderwood (Harvard Medical School), Gary Landreth (Case Western Reserve University), Tamara Maes, PhD (Oryzon Genomics S.A.), David M. Roy (Memorial Sloan Kettering Cancer Center), Stephen Strittmatter (Yale University School of Medicine), Li Huei Tsai (Massachusetts Institute of Technology), Raymond Scott Turner (Georgetown University), Claes Wahlestedt (University of Miami Miller School of Medicine), Hui Zheng (Baylor College of Medicine)
Does having cancer decrease your risk of developing neurodegenerative diseases? Why do many cancer drug targets overlap with targets for neurodegenerative diseases? This meeting will address these questions to help advance therapeutic development.
Thursday, May 28, 2015 | 8:00 AM - 3:00 PM
Keynote Speaker: Craig B. Thompson (Memorial Sloan-Kettering Cancer Center)
Speakers: John Blenis (Weill Cornell Medical College ), Selina Chen-Kiang (Weill Cornell Medical College), Lydia Finley (Memorial Sloan-Kettering Cancer Center), Alec Kimmelman (Harvard Medical School), Christian Metallo (University of California, San Diego ), Elena Piskounova (University of Texas Southwestern Medical Center ), Sohail Tavazoie (The Rockefeller University), Matthew G. Vander Heiden (Massachusetts Institute of Technology)
This symposium will highlight insights into tumor metabolism from leaders in the field and explore how this information is being used to design safe and effective, metabolism-targeted therapies.
Tuesday, May 26, 2015 | 8:30 AM - 4:30 PM
Speakers: Richard Allen (Pfizer, Inc.), John Burke (Applied BioMath), Nitin Mehrotra (US Food and Drug Administration), Sian Ratcliffe (Pfizer Inc), Matthew Rizk (Merck & Co, Inc), Tim Rolph (Pfizer, Inc.), Vikram Sinha (US Food and Drug Administration), Peter Sorger (Harvard Medical School), Paul Watkins (Hamner-UNC Institute for Drug Safety Sciences)
Quantitative Systems Pharmacology (QSP) has been used successfully in drug discovery and development, yet lacks industry-wide adoption. This symposium highlights past successes and future challenges of using QSP in preclinical and clinical research.
Organizers: Nathalie Breysse (Lundbeck Research USA), Elena Dale (Lundbeck Research USA), and Sonya Dougal (The New York Academy of Sciences)
Non-motor symptoms are common but often overlooked in Parkinson's disease. This eBriefing examines new approaches to studying disease mechanisms, which could lead to a better understanding of pathogenesis and to the development of new therapies.
Edited by Claudio Carini
Discusses the development of biomarker-based companion diagnostics to optimize diagnosis and treatment choices.
Edited by Matthew E. Fink
(Weill Cornell Medical College), Jack D. Barchas
(Weill Cornell Medical College), and Javaid I. Sheikh
(Weill Cornell Medical College in Qatar)
Discussions of the latest translational research, advanced brain imaging, & novel diagnostics
Edited by Annals of the New York Academy of Sciences
This Annals volume discusses progress in neuroscience that translates to new treatments for psychiatric illness, with a focus on progress in developing quantitative endpoints to measure disease progression and response to therapy in depression and schizophrenia.
A recent conference held at the Academy asked a downright outrageous question: Can dementia be prevented by making changes to your diet? In this podcast we look at what the answers might be.
In the second of a two-part series, experts look at the links between health and nutrition. They examine everything from how nutrition impacts hospital stays, to cancer and aging, to developing food science innovations, and improving diet.
In this first of a two-part series, experts from various sectors explore the available options to reduce "hidden hunger"—micronutrient deficiencies in a population.
February 23, 2010
Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
April 28, 2009
Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.